Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Sees Significant Increase in Short Interest

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) saw a large increase in short interest in August. As of August 31st, there was short interest totalling 17,100 shares, an increase of 271.7% from the August 15th total of 4,600 shares. Currently, 2.6% of the company’s stock are short sold. Based on an average trading volume of 435,500 shares, the days-to-cover ratio is presently 0.0 days.

Titan Pharmaceuticals Stock Up 0.2 %

Shares of Titan Pharmaceuticals stock traded up $0.01 during trading on Friday, hitting $5.54. The company’s stock had a trading volume of 27,438 shares, compared to its average volume of 181,703. The company has a fifty day simple moving average of $5.84 and a two-hundred day simple moving average of $6.52. Titan Pharmaceuticals has a 52 week low of $4.24 and a 52 week high of $14.80.

Titan Pharmaceuticals (NASDAQ:TTNP) last released its quarterly earnings data on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on shares of Titan Pharmaceuticals in a research note on Saturday. They issued a “sell” rating for the company.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.